Doble poder por una sola causa
Reduce la PIO* en un 40% asegurándole a su paciente con Glaucoma y/o Hipertensión Ocular lograr la PIO* meta 1
Disminuye significativamente la progresión del daño del campo visual 2
* PIO: Presión Intraocular
1. Jason Yeh et al. Rational use of the fixed combination of Dorzolamide-Timolol in the management of raised intraocular pressure and glaucoma. Clinical Ophthalmology 2008; 2(2):389-399 2. Martínez Antonio et al. Effects of Dorzolamide 2% Added to Timolol Maleate 0.5% on Intraocular Pressure, Retrobulbar Blood Flow, and the Progression of Visual Field Damage in Patients with Primary Open-Angle Glaucoma: A Single-Center, 4-Year, Open-Label Study. Clin Ther. 2008;30:1120–1134
1. Yeh Jason et al. Ratinale use of the fixed combination of Dorzolamide-Timolol in the management of raised intraocular pressure and glaucoma. Clinical Ophthalmology 2008; 2(2):389-399 2. Martínez Antonio et al. Effects of Dorzolamide 2% Added to Timolol Maleate 0.5% on Intraocular Pressure, Retrobulbar Blood Flow, and the Progression of Visual Field Damage in Patients with Primary Open-Angle Glaucoma: A Single-Center, 4-Year, Open-Label Study. Clin Ther. 2008;30:1120–1134 3. Gugleta Konstantin et al. Experience with cosopt, the fixed combination of timolol and dorzolamide, After switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists offices CURRENT MEDICAL RESEARCH AND OPINION. 2003; Vol. 19(4): 330-335
Acerca se Sun Pharma
Visión y valores
Hitos y Reconocimientos
Operaciones
Productos
Innovación
Calidad
Inversionistas
Políticas
Reunión de la Junta
Reportes anuales
Patrón Accionario
Responsabilidad
Responsabilidad Social
Medio Ambiente
Acceso rápido
Contáctenos
Reacciones adversas
Quejas de calidad de producto
Permiso de Publicidad No.233300201B3843
Aviso de Publicidad No.2309092002C00213